Company Search:
Advanced Search
Sponsored Links
Avacta Group Plc Company Snapshot
Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company's segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. The Company's in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies. It focuses on its Affimer technology, which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development.

Sales Analysis. Avacta Group Plc reported sales of £2.17 million (US$2.65 million) for the fiscal year ending July of 2016. This represents an increase of 19.4% versus 2015, when the company's sales were £1.81 million. Despite this increase, sales are still well below the level achieved in 2014, when Avacta Group Plc reported sales of £3.18 million.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Avacta Group Plc
  Stock Performance Chart for Avacta Group Plc
  Stock Data: Recent Stock Performance:
  Current Price (10/21/2016): 89.00p
(Figures in Pounds Sterling)
1 Week 0.0%   13 Weeks -9.6%  
4 Weeks 5.3%   52 Weeks -36.7%  
Avacta Group Plc Key Data:
  Ticker: AVCT Country: United Kingdom
  Exchanges: LON Major Industry: Health Care Equipment & Services
    Sub Industry: Analytical Instruments
  2016 Sales 2,165,000
(Year Ending Jan 2017).
Employees: 83
  Currency: Pounds Sterling Market Cap: 60,857,561
  Fiscal Yr Ends: July Shares Outstanding: 68,379,282
  Share Type: Ordinary Closely Held Shares: 21,734,536
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.